
News|Articles|September 1, 2005
FDA actions in brief
Valsartan (Diovan, Novartis) received an expanded indication for reducing cardiovascular mortality in patients who are at high risk due to left ventricular failure or dysfunction after myocardial infarction.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves Lipfendra, first oral PCSK9 inhibitor
2
How the most favored nation drug pricing policy is quietly reshaping drug development and clinical research
3
Capital Rx is now Judi Rx in a company rebrand
4
FTC secures settlement with Caremark, locks in up to $8.5 billion in consumer savings
5

























